Shire announces top-line results for phase 2 trial of SHP607 in premature infants
Shire announced that its Phase 2 study evaluating an investigational protein replacement, SHP607, did not meet its primary endpoint of reducing the severity of retinopathy of prematurity, a rare eye condition. The study, however, demonstrated clinically relevant effects in secondary endpoints. June 30, 2016